Jointly Provided by American Academy of CME and CheckRare CE

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Start date: June 1, 2023
End date: May 31, 2024
Estimated time to complete: 60 minutes

Activity Description

Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.

Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new therapies under investigation which may impact treatment in the future.

This 60-minute CME program, hosted by Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current best practices for diagnosing and managing patients with wAIHA.

Activity Faculty

Irina Murakhovskaya, MD
Montefiore Medical Center
Albert Einstein College of Medicine
New York, NY

Bruno Fattizzo, MD
University of Milan
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Milan, Italy

Target Audience

This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other healthcare providers may also participate.

Learning Objectives

After participating in the activity, learners should be better able to:

• Describe the difference between primary and secondary wAIHA
• List best practices for diagnosing wAIHA
• Describe common complications associated with wAIHA
• Explain current treatment recommendations for patients with wAIHA and the evidence which supports them
• Describe potential therapies in development for treating patients with wAIHA

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other HCPs

Other members of the care team will receive a certificate of participation.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the post-test and program evaluation.

Disclosures

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educators/Planners

Irina Murakhovskaya, MD discloses the following relevant relationships: Advisory Board/Consultant: Sanofi, Novartis, Alexion, Janssen, Apellis, Rigel; Grant/Research Support: Sanofi, Novartis, Alexion, Janssen, Apellis, Rigel, Incyte

Bruno Fattizzo, MD discloses the following relevant relationships: Advisory Board/Consultant: Agios, Alexion, Annexon, Bristol Myers Squibb, Janssen, Sobi; Speaker’s Bureau: Bristol Myers Squibb, Janssen, Novartis, Sobi

Planning Committee

American Academy of CME, Inc. and CheckRare CE planners: No relevant financial relationships with ineligible companies to disclose.

This activity will review off-label or investigational information about the following medications — prednisone, rituximab, azathioprine, cyclosporine, cyclophosphamide, mycophenolate, lemtuzumab, daratumumab, ofatumumab, tabalumab, povetacicept, obexelimab, ibrutinib, rilzabrutinib, venetoclax, fostamatinib, sovleplenib, nipocalimab, orilanolimab, annexion-005, eculizumab, pegcetacoplan, bortezomib.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).